Log in | Register

Variants at the promoter of the interleukin-6 gene are associated with severity and outcome of pneumococcal community-acquired pneumonia

Ignacio Martín-Loeches| Jordi Solé-Violán| Felipe Rodríguez de Castro| M. Isabel García-Laorden| Luis Borderías| José Blanquer| Olga Rajas| M. Luisa Briones| Javier Aspa| Estefanía Herrera-Ramos| José Alberto Marcos-Ramos| Ithaisa Sologuren| Nereida González-Quevedo| José María Ferrer-Agüero| Judith Noda| Carlos Rodríguez-Gallego
Original
Volume 38, Issue 2 / February , 2012

Pages 256 - 262

Abstract

Purpose

Conflicting results about the role of genetic variability at IL6, particularly the -174 G/C single nucleotide polymorphism (SNP), in sepsis have been reported. We studied the genetic variability at IL6 in patients with community-acquired pneumonia (CAP) and pneumococcal CAP (P-CAP).

Methods

This was a multicenter, prospective observational study. IL6 -174 was analyzed in 1,227 white Spanish patients with CAP (306 with P-CAP). IL6 1753 C/G (= 750), 2954 G/C (N = 845), and haplotypes defined by these SNPs were also studied.

Results

In CAP patients the genotype -174 GG were associated with protection against acute respiratory distress syndrome (ARDS) (p = 0.008, OR = 0.4, 95% CI 0.2–0.8). No other significant associations were observed. However, in patients with P-CAP multivariate analysis adjusted for age, gender, co-morbidity, hospital of origin, and severity (pneumonia severity index, PSI) showed that the IL6 -174 GG genotype was protective against the development of ARDS (p = 0.002, OR = 0.25, 95% CI 0.07–0.79), septic shock (p = 0.006, OR = 0.46, 95% CI 0.18–0.79), and multiple organ dysfunction syndrome (= 0.02, OR = 0.53, 95% CI 0.27–0.89). P-CAP patients homozygous for IL6 -174 G also showed a higher survival in a logistic regression analysis adjusted for age, gender, co-morbidity, hospital of origin, and PSI (= 0.048, OR = 0.27, 95% CI 0.07–0.98).

Conclusions

Our results indicate that the IL-6 -174 GG genotype is associated with lower severity and mortality in patients with P-CAP. This effect was higher than that observed in patients with CAP irrespective of the causal pathogen involved. Our results highlight the importance of the causal pathogen in genetic epidemiological studies in sepsis.

Keywords

References

  1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27–S72
    • View reference on PubMed
    • View reference on publisher's website
  2. Arcaroli J, Fessler MB, Abraham E (2005) Genetic polymorphisms and sepsis. Shock 24:300–312
    • View reference on PubMed
    • View reference on publisher's website
  3. Jones SA (2005) Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 175:3463–3468
    • View reference on PubMed
  4. Schluter B, Raufhake C, Erren M, Schotte H, Kipp F, Rust S, Van AH, Assmann G, Berendes E (2002) Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med 30:32–37
    • View reference on PubMed
    • View reference on publisher's website
  5. Burzotta F, Iacoviello L, Di Castelnuovo A, Glieca F, Luciani N, Zamparelli R, Schiavello R, Donati MB, Maseri A, Possati G, Andreotti F (2001) Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am J Cardiol 88:1125–1128
    • View reference on PubMed
    • View reference on publisher's website
  6. International Union of Immunological Societies Expert Committee on Primary Immunodeficiencies, Notarangelo LD, Fischer A, Geha RS, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, Etzioni A, Hammartröm L, Nonoyama S, Ochs HD, Puck J, Roifman C, Seger R, Wedgwood J (2009) Primary immunodeficiencies: 2009 update. International Union of immunological societies expert committee on primary immunodeficiencies. J Allergy Clin Immunol 124:1161–1178
    • View reference on PubMed
    • View reference on publisher's website
  7. Feezor RJ, Oberholzer C, Baker HV, Novick D, Rubinstein M, Moldawer LL, Pribble J, Souza S, Dinarello CA, Ertel W, Oberholzer A (2003) Molecular characterization of the acute inflammatory response to infections with gram-negative versus gram-positive bacteria. Infect Immun 71:5803–5813
    • View reference on PubMed
    • View reference on publisher's website
  8. Yu SL, Chen HW, Yang PC, Peck K, Tsai MH, Chen JJ, Lin FY (2004) Differential gene expression in gram-negative and gram-positive sepsis. Am J Respir Crit Care Med 169:1135–1143
    • View reference on PubMed
    • View reference on publisher's website
  9. Abe R, Oda S, Sadahiro T, Nakamura M, Hirayama Y, Tateishi Y, Shinozaki K, Hirasawa H (2010) Gram-negative bacteremia induces greater magnitude of inflammatory response than Gram-positive bacteremia. Crit Care 14:R27
    • View reference on PubMed
    • View reference on publisher's website
  10. Cooper DN, Nussbaum RL, Krawczak M (2002) Proposed guidelines for papers describing DNA polymorphism-disease associations. Hum Genet 110:207–208
    • View reference on PubMed
    • View reference on publisher's website
  11. Cardon LR, Bell JL (2001) Association study designs for complex diseases. Nat Rev Genet 2:91–99
    • View reference on PubMed
    • View reference on publisher's website
  12. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, SCCM/ESICM/ACCP/ATS/SIS (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 31:1250–1256
    • View reference on PubMed
    • View reference on publisher's website
  13. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243–250
    • View reference on PubMed
    • View reference on publisher's website
  14. Solé-Violán J, de Castro F, García-Laorden MI, Blanquer J, Aspa J, Borderías L, Briones ML, Rajas O, Carrondo IM, Marcos-Ramos JA, Ferrer Agüero JM, Garcia-Saavedra A, Fiuza MD, Caballero-Hidalgo A, Rodriguez-Gallego C (2010) Genetic variability in the severity and outcome of community-acquired pneumonia. Respir Med 104:440–447
    • View reference on PubMed
    • View reference on publisher's website
  15. Sutherland AM, Walley KR, Manocha S, Russell JA (2005) The association of interleukin 6 haplotype clades with mortality in critically ill adults. Arch Intern Med 165(1):75–82
    • View reference on PubMed
    • View reference on publisher's website
  16. Terry CF, Loukaci V, Green FR (2000) Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 275:18138–18144
    • View reference on PubMed
    • View reference on publisher's website
  17. Geppert A, Dorninger A, Delle-Karth G et al (2006) Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit Care Med 34:2035–2042
    • View reference on PubMed
    • View reference on publisher's website
  18. Schaaf B, Rupp J, Müller-Steinhardt M, Kruse J, Boehmke F, Maass M, Zabel P, Dalhoff K (2005) The interleukin-6–174 promoter polymorphism is associated with extrapulmonary bacterial dissemination in Streptococcus pneumoniae infection. Cytokine 31:324–328
    • View reference on PubMed
    • View reference on publisher's website
  19. Waterer GW, Bruns AH (2010) Genetic risk of acute pulmonary infections and sepsis. Expert Rev Respir Med 4:229–238
    • View reference on PubMed
    • View reference on publisher's website
  20. Picard C, Puel A, Bustamante J, Ku CL, Casanova JL (2003) Primary immunodeficiencies associated with pneumococcal disease. Curr Opin Allergy Clin Immunol 3:451–459
    • View reference on PubMed
    • View reference on publisher's website
  21. Garcia-Laorden MI, Rodriguez de Castro F, Sole-Violan J, Rajas O, Blanquer J, Borderias L, Aspa J, Briones ML, Saavedra P, Marcos-Ramos JA, Gonzalez-Quevedo N, Sologuren I, Herrera-Ramos E, Ferrer JM, Rello J, Rodriguez-Gallego C (2011) Influence of genetic variability at the surfactant proteins A and D in community-acquired pneumonia: a prospective, observational, genetic study. Crit Care 15:R57
    • View reference on PubMed
    • View reference on publisher's website
  22. Poli V, Maritano D (2003) IL-6 knockout mice. In: Fantuzzi G (ed) Cytokine knockouts. Humana, Totowa, pp 213–234
  23. Thornton JA, Durick-Eder K, Tuomanen EI (2010) Pneumococcal pathogenesis: “innate invasion” yet organ-specific damage. J Mol Med 88:103–107
    • View reference on PubMed
    • View reference on publisher's website
  24. Pirofski LA, Casadevall A (2009) Rethinking T cell immunity in oropharyngeal candidiasis. J Exp Med 206:269–273
    • View reference on PubMed
    • View reference on publisher's website
  25. van der Poll T, Keogh CV, Guirao X et al (1997) Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis 176:439–444
    • View reference on PubMed
    • View reference on publisher's website
  26. Leon LR, White AA, Kluger MJ (1998) Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice. Am J Physiol 275:R269–R277
    • View reference on PubMed
  27. Mold C, Nakayama S, Holzer TJ, Gewurz H, Du Clos TW (1981) C-reactive protein is protective against Streptococcus pneumoniae infection in mice. J Exp Med 154:1703–1708
    • View reference on PubMed
    • View reference on publisher's website
  28. Szalai AJ, Briles DE, Volanakis JE (1995) Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J Immunol 155:2557–2563
    • View reference on PubMed
  29. Thomas-Rudolph D, Du Clos TW, Snapper CM, Mold C (2007) C-reactive protein enhances immunity to Streptococcus pneumoniae by targeting uptake to Fc gamma R on dendritic cells. J Immunol 178:7283–7291
    • View reference on PubMed
  30. Solé-Violán J, García-Laorden MI, Marcos-Ramos JA, Rodríguez de Castro F, Rajas O, Borderías L, Briones ML, Herrera-Ramos E, Blanquer J, Aspa J, Florido Y, García-Bello MA, Ferrer Agüero JM, Sologuren I, Rodriguez-Gallego C (2011) The Fcγ receptor IIA-H/H131 genotype is associated with bacteremia in pneumococcal community-acquired pneumonia. Crit Care Med 39:1388–1393
    • View reference on PubMed
    • View reference on publisher's website
  31. Barber RC, Chang LY, Arnoldo BD, Purdue GF, Hunt JL, Horton JW, Aragaki CC (2006) Innate immunity SNPs are associated with risk for severe sepsis after burn injury. Clin Med Res 4:250–255
    • View reference on PubMed
    • View reference on publisher's website
  32. Yandiola PP, Capelastegui A, Quintana J, Diez R, Gorordo I, Bilbao A, Zalacain R, Menendez R, Torres A (2009) Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia. Chest 135:1572–1579
    • View reference on PubMed
    • View reference on publisher's website
  33. Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A (2008) A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 133:610–617
    • View reference on PubMed
    • View reference on publisher's website
  34. Chalmers JD, Mandal P, Singanayagam A, Akram AR, Choudhury G, Short PM, Hill AT (2011) Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med 37:1409–1420

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement